Background-Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice. Methods and Results-We studied 47 040 patients with myocardial infarction treated with percutaneous coronary intervention, who received either clopidogrel or prasugrel within 24 hours of admission at 361 US hospitals from July 2009 to June 2011 using the merged Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines and CathPCI Registry database. Hierarchical logistic regression modeling was used to determine factors independently associated with in-hospital ADPri switching. Among 40 531 patients treated initially in-hospital with clopidogrel, 2125 (5.2%) were discharged on prasugrel; this frequency steadily increased from 0% to 7% during the study period. Among 6509 patients treated initially in-hospital with prasugrel, 751 (11.5%) were discharged on clopidogrel. The frequency of this switch increased from 6% to 18% during the first 2 quarters of the study period and decreased to 9% by the end. Switching clopidogrel to prasugrel was associated with high-risk angiographic characteristics (thrombotic, long, and bifurcating lesions), reinfarction in-hospital, and private health insurance coverage. Older age, previous cerebrovascular event, in-hospital coronary artery bypass grafting, in-hospital bleeding, and warfarin use at discharge were associated with switching prasugrel to clopidogrel. Conclusions-Clopidogrel and prasugrel are not uncommonly switched in-hospital in patients with myocardial infarction undergoing percutaneous coronary intervention. In contemporary US practice, in addition to risk for bleeding and recurrent ischemic events, medical drug coverage is a major determinant of ADPri selection. (Circ Cardiovasc Interv. 2014;7:585-593.)
D ual antiplatelet therapy with aspirin and a platelet ADP receptor inhibitor is the cornerstone of treatment to prevent recurrent atherothrombotic events in patients with myocardial infarction (MI), particularly those treated with percutaneous coronary intervention (PCI). 1, 2 Although clopidogrel has been the primary ADP receptor inhibitor used in the past decade, higher potency ADP receptor inhibitors, such as prasugrel and ticagrelor, are now available for clinical use in the United States. These agents have a more rapid and consistent antiplatelet effect and have demonstrated greater reduction in atherothrombotic events when compared with clopidogrel. 3, 4 However, these agents are associated with higher risk of bleeding; are more costly; and differ in side effect profiles, drug interactions, contraindications, precautions for use, and dosing regimen. 5 When initiating ADP receptor inhibitors early during hospitalization for MI, information about the risk of recurrent thrombotic events, bleeding, patient adherence to medication, and affordability of drug may not be known. Given availability of several ADP receptor inhibitors, optimizing such factors during hospitalization by switching drug regimen may be a consideration for some patients. Currently, there is a paucity of data about the contemporary practice of switching between ADP receptor inhibitor drugs. Evaluating factors associated with switching ADP receptor inhibitors is important to determine whether decisions for selection of ADP receptor inhibitors are made in accordance with the available literature and treatment guidelines.
In this study, we merged data from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines (ACTION Registry-GWTG) and the National Cardiovascular Data Registry CathPCI Registry to determine the temporal trends and patient factors associated with switching ADP receptor inhibitors in-hospital among patients with MI treated with PCI. We specifically focused on the switch from clopidogrel to prasugrel and from prasugrel to clopidogrel.
Methods

Data Source
The ACTION Registry-GWTG and CathPCI Registry have been previously described. [6] [7] [8] Briefly, the ACTION Registry-GWTG is an ongoing quality improvement registry of consecutive patients with both ST-segment-elevation MI (STEMI) and non-ST-elevation acute coronary syndrome (NSTEACS), who are treated at >700 participating centers across the United States. The CathPCI Registry catalogs data on cardiac catheterization and PCI procedures from >1500 sites. Both registries have a comprehensive data quality program, including data quality report specifications for data capture and transmission, as well as an auditing program. 9 Data on patient demographics, medical history, and MI event, including type and choice of therapy, were obtained from the ACTION Registry-GWTG. In addition, information abot home, in-hospital, and discharge medications, including ADP receptor inhibitors, was also obtained from ACTION Registry-GWTG. Procedural data, including complexity of disease (number, degree, and location of stenosis), devices deployed, and detailed peri-procedural outcomes, were obtained from the CathPCI Registry. All participating institutions were required to comply with local regulatory and privacy guidelines and, if required, to secure institutional review board approval. Because data were used primarily at the local site for quality improvement, sites were granted a waiver of informed consent under the common rule.
Linking ACTION Registry-GWTG and CathPCI Registry
For the purpose of this analysis, the ACTION Registry-GWTG and CathPCI Registry data sets were linked to create a novel single file of patients with records in both registries. Only hospitals meeting the quality standards in each registry were included, 9 and the study timeframe was restricted to patients discharged on or after July 1, 2009, until September 30, 2011, to limit the data to the period covered by version 4 of the CathPCI Registry and Food and Drug Administration approval of prasugrel on July 10, 2009. Unique patient identification files were created for each patient record in each registry using the concatenation of social security number, date of birth, and sex. Any record with a null or invalid value for social security number, date of birth, or sex was excluded. The 2 registry data sets were then reduced to files of unique combinations of social security number, date of birth, and sex. Finally, the 2 data sets were merged using this unique patient identifier and only an exact match on all 3 fields was accepted. This merge resulted in a total of 104 367 matched patients with a record in both ACTION Registry-GWTG and CathPCI Registry (Figure 1 ). All the data for admissions for patients in both the ACTION Registry-GWTG and the CathPCI Registry were transferred to the American College of Cardiology-Yale Data Analytic Center for further matching and analyses.
Analysis Population
For this analysis, hospital admissions for acute MI with discharges between July 1, 2009, and June 30, 2011, from both registries were identified based on the combination of unique patient identifier, discharge date, and hospital identifier. Admissions in which the patients did not receive a PCI were excluded because certain considerations for primary ADP receptor inhibitor selection or switching are potentially different between those treated with PCI and those managed medically or with coronary artery bypass grafting (CABG). Admissions in each registry for hospitals not participating in both registries were also excluded. Hospital admissions were then linked between the 2 registries using the combination of unique patient identifier, discharge date, and hospital identifier. Finally, for patients who had >1 MI admission treated with PCI during the study time period (n=1049), we randomly selected 1 admission to reflect the overall analysis population, which includes patients with and without previous MI treated with PCI. This resulted in a total of 58 413 admissions (or patients) from 365 hospitals in the final merge of the 2 registries.
For this analysis, we also excluded patients transferred to another facility (n=587), those who died in hospital (n=1619), those treated with ticlodipine in hospital (n=140), and those not discharged on either clopidogrel or prasugrel (n=65). In addition, because the ACTION registry-GWTG only collects in-hospital medication use within the first 24 hours after presentation and at hospital discharge, those not treated initially with clopidogrel or prasugrel within 24 hours of admission (n=8962) were also excluded because in-hospital drug switching could not be determined in this cohort. Thus, the final cohort for
WHAT IS KNOWN
• Novel ADP receptor inhibitors prasugrel and ticagrelor have a more rapid and consistent antiplatelet effect and have demonstrated greater reduction in atherothrombotic events when compared with clopidogrel.
• However, these agents are associated with higher risk of bleeding; are more costly; and differ in side effect profiles, drug interactions, contraindications, precautions for use, and dosing regimen.
• Given availability of several ADP receptor inhibitors, optimizing such factors during hospitalization by switching drug regimen may be a consideration for some patients.
WHAT THE STUDY ADDS
• Clopidogrel and prasugrel are not uncommonly switched in-hospital among patients with myocardial infarction treated with percutaneous coronary intervention.
• Switch from initial in-hospital use of clopidogrel to discharge on prasugrel is associated with angiographic and clinical characteristics for increased risk of recurrent thrombotic events, as well as private health insurance coverage to cover the cost of the drug, whereas switch from initial in-hospital use of prasugrel to clopidogrel at discharge is primarily associated with risk of bleeding. this analysis comprised 47 040 patients with MI treated with PCI during hospitalization and with either clopidogrel or prasugrel within 24 hours of hospital admission, as well as at hospital discharge.
Study Definition of ADP Receptor Inhibitor Switch
Among patients treated initially in-hospital with clopidogrel, switch was defined as discharge from the hospital on prasugrel, and among patients treated initially in-hospital with prasugrel, switch was defined as discharge from the hospital on clopidogrel. Ticagrelor was not approved in the United States during the study period, and thus information on its use was not available.
Statistical Analysis
Among patients treated initially in-hospital with clopidogrel, those switched to and discharged on prasugrel were compared with patients discharged on clopidogrel, whereas among patients treated initially inhospital with prasugrel, those switched to and discharged on clopidogrel were compared with patients discharged on prasugrel. Descriptive statistics were summarized as median (25th, 75th percentiles) for continuous variables and percentages for categorical variables. Differences between groups were compared using Wilcoxon rank-sum test for continuous variables and Pearson χ 2 test for categorical variables.
Temporal Trends in In-Hospital ADP Receptor Inhibitor Switching
Overall frequency and quarterly temporal trends in the rate of in-hospital switching between clopidogrel and prasugrel were determined for the 8 quarters of data collection between July 1, 2009, and June 30, 2011, and tested using the Cochran Armitage trend test. We also determined temporal trends in rate of in-hospital switching between clopidogrel and prasugrel separately for patients presenting with STEMI and NSTEACS.
Hospital Variability and Factors Associated With In-Hospital ADP Receptor Inhibitor Switching
We determined variability in the rate of in-hospital ADP receptor switch across hospitals by determining the proportion of patients with ADP receptor inhibitor switch at each hospital. Analyses were conducted separately for switch from clopidogrel to prasugrel and from prasugrel to clopidogrel. For these analyses, only hospitals with ≥5 patients in the given subcohort were included.
Among the cohort of patients treated initially in-hospital with clopidogrel, factors independently associated with switch and discharge on prasugrel were identified using a hierarchical logistic regression model with an intercept at hospital-level as a random effect. This hierarchical model was used to account for site confounding because hospitals have different practices about availability and selection of ADP receptor inhibitor therapy. Factors tested in the model included transfer from another hospital, patient demographics (age, sex, race, weight, and health insurance status), medical history (diabetes mellitus, hypertension, dyslipidemia, current/recent smoking, MI, PCI, CABG, heart failure, stroke or transient ischemic attack [TIA], atrial fibrillation/flutter, dialysis), medical therapy before admission (aspirin, clopidogrel, and prasugrel), features on hospital presentation (STEMI, heart failure, shock, and cardiac arrest), angiographic characteristics (culprit lesion length, presence of thrombus, bifurcating culprit lesion, culprit lesion in proximal left anterior descending artery, culprit in bypass graft, multivessel disease, multivessel PCI, postprocedure thrombolysis in MI flow), stent characteristics (bare metal and drug-eluting), number of PCI procedures during hospitalization, laboratory values (peak troponin, lowest hemoglobin, and peak creatinine), in-hospital events (reinfarction, stroke, bleeding, and CABG), and discharge on warfarin. Proportion of missing values was small (<1%) for all the considered variables. Missing categorical variables were imputed to the most frequent value; missing continuous variables were imputed to the median of the nonmissing values. Backward selection was used to identify significant variables at a critical level of 0.05. The model was reconstructed using the same candidate variables in the cohort of patients treated initially in-hospital with prasugrel to determine factors independently associated with switch and discharge on clopidogrel. Analyses were done using SAS version 9.3 (SAS Institute Inc, Cary, NC), and results are presented as odds ratios with 95% confidence intervals.
Results
Among the 47 040 patients with MI who underwent PCI, 40 531 (86.1%) were treated initially in-hospital with clopidogrel, and 6509 (13.9%) were treated initially in-hospital with prasugrel. During the entire time period of analysis, 2215 (5.2%) of the 40 531 patients treated initially with clopidogrel were switched to and discharged on prasugrel, whereas 751 (11.5%) of the 6509 patients treated initially with prasugrel were switched to and discharged on clopidogrel. The demographic and clinical characteristics of the patients are presented in Table 1 . Among patients treated initially with clopidogrel, those switched to prasugrel were younger, of greater body weight, more likely to be privately insured, and less likely to be women or have previous stroke or TIA. In contrast, patients switched to prasugrel to clopidogrel were older, of lower body weight, more likely to be women and have previous stroke or TIA, and less likely to be privately insured.
Temporal Trends in Rate of ADP Receptor Inhibitor Switching
The rate of switch from clopidogrel to prasugrel increased from 0% to 7% during the duration of the study period (Figure 2) . Temporal trends in rate of switch from clopidogrel to prasugrel were similar for patients presenting with STEMI and NSTEACS ( Figure 3 ). In the overall population, the rate of switch from prasugrel to clopidogrel increased initially from 6% to 18%, decreased abruptly in the second quarter of 2010, and then declined gradually to 9% by the end of the study period ( Figure 2 ). At the start of the study period, rate of in-hospital switch from prasgurel to clopidogrel was greater among NSTEACS when compared with patients with STEMI.
During the course of the study period, consistent with the overall study cohort, rate of switching from prasugrel to clopidogrel followed similar temporal trends in both subgroups of patients ( Figure 3 ).
Hospital Variability and Factors Associated With In-hospital ADP Receptor Inhibitor Switching
We observed wide variation in the rate of ADP receptor inhibitor switching across hospitals, both for switch from clopidogrel to prasugrel (median, 4.1%; Q1, Q3: 1.3%, 7.8%; minimum, maximum, 0.0%, 42.9%) and from prasugrel to clopidogrel (median, 6.7%; Q1, Q3: 0.0%, 16.7%; minimum, maximum: 0.0%, 86.0%; Figure 4 ). Among patients treated initially in-hospital with clopidogrel, switch to and discharge on prasugrel was most strongly associated with recurrent PCI procedures during index hospitalization. High angiographic risk characteristics, including intracoronary thrombus, longer lesion length, bifurcating culprit lesion, and multivessel PCI, and higher clinical risk characteristics including previous PCI, diabetes mellitus, and in-hospital reinfarction, were also associated with switch from clopidogrel to prasugrel (Table 2) . When compared with no insurance, private health insurance coverage was also associated with switch to prasugrel, but Medicare or Medicaid coverage was associated with continuation and discharge on clopidogrel. Factors associated with increased risk of bleeding, including older age, previous stroke or TIA, atrial fibrillation/flutter, and in-hospital treatment with CABG, were also associated with continuation and discharge on clopidogrel. A small proportion (2.2%; n=48) of the 2167 patients with previous stroke or TIA who were treated initially with clopidogrel were discharged on prasugrel.
Among patients treated initially in-hospital with prasugrel, switch to and discharge on clopidogrel was most strongly associated with observed bleeding events in hospital and factors subtending increased bleeding risk, including older age, previous stroke or TIA, in-hospital treatment with CABG, and discharge on warfarin. Among this prasugrel-treated cohort, continuation and discharge on prasugrel was associated most strongly with health insurance coverage, both private and Medicare or Medicaid. Other factors include STEMI presentation, treatment with drug-eluting stent, treatment with prasugrel before admission, and increased body weight (Table 3 ). Among 116 patients with previous stroke or TIA who were initially treated with prasugrel, 78 (67.2%) were continued and discharged on prasugrel.
Discussion
In this large sample of patients with MI treated with PCI in the United States, several important observations about the practice of in-hospital ADP receptor inhibitor switching emerge. ADP receptor inhibitors are not uncommonly switched in-hospital with switch from prasugrel to clopidogrel occurring with similar frequency at the end of the study period as the switch from clopidogrel to prasugrel. After initial in-hospital treatment with clopidogrel, switch to prasugrel was most strongly associated with repeat PCI procedures during hospitalization, angiographic and clinical characteristics predictive of higher risk of recurrent thrombotic events, and affordability of the drug with private health insurance coverage. Conversely, switch to clopidogrel after initial treatment with prasugrel was most strongly associated with in-hospital bleeding events and clinical characteristics predictive of bleeding.
The Greek multicenter registry showed that the rate of inhospital switch from clopidogrel to prasugrel or ticagrelor was 46%, and the rate of in-hospital switch from prasugrel or ticagrelor to clopidogrel was 6.5%. 10 Data for this study were collected between January 2012 and June 2013, a period when novel agents were more readily available. Consistent with an overall increase in prasugrel use since its approval in July 2009, 11 the rate of in-hospital switch from clopidogrel to prasugrel also steadily increased in the United States. Temporal trend in frequency of switch was similar for patients with STEMI and NSTEACS. Switching clopidogrel to prasugrel has occurred, despite lack of recommendations in the guidelines and minimal clinical data evaluating the safety of this practice. 3, 12 Pharmacodynamic data, however, are reassuring that platelet reactivity with prasugrel 60-mg loading dose added to clopidogrel 600-mg loading dose is not significantly different when compared with prasugrel 60-mg loading dose alone, 13 and thus risk for bleeding with loading dose of prasugrel on top of platelet inhibition with clopidogrel is unlikely to be in excess of that with prasugrel used alone.
The rate of switch from prasugrel to clopidogrel was high shortly after approval of prasugrel, likely because of lack of familiarity with the new drug and concern about availability in outpatient pharmacies. However, there was an abrupt decrease in the rate of switch from prasugrel to clopidogrel in the second quarter of 2010, coinciding with the Food and Drug Administration warning about reduced effectiveness of clopidogrel among patients with polymorphisms in the gene coding for the CYP2C19 enzyme. The frequency of switch from prasugrel to clopidogrel stabilized toward the end of study period in June 2011 approximating the rate of switch from clopidogrel to prasugrel. Although switching from prasugrel to clopidogrel results in increased platelet reactivity with potential unmasking of a group of nonresponders to clopidogrel, the clinical consequences remain to be studied. 14 The median hospital rate of ADP receptor inhibitor switching was low; however, there was significant variation in the frequency of ADP receptor inhibitor switching among hospitals, suggesting selective switching of drugs. Although the ultimate reasons for switching drug therapy in our study population are not known, several factors make in-hospital switching of ADP receptor inhibitors particularly appealing. Although there is literature to support early precatheterization use of clopidogrel in NSTEACS, 15 data do not support the use of prasugrel before delineation of coronary anatomy. 16 Thus, unless ADP receptor inhibitors are withheld until coronary angiography, using prasugrel requires active switching during or after catheterization-a practice not explicitly tested in large randomized trials. In addition, in some cases, detailed information about patient ischemic and bleeding risk, treatment preference, adherence to medication, and socioeconomic status is not known earlier in the hospitalization. As additional information is gathered after admission, the optimal drug for the individual patient, with consideration of the differences between the drugs, may be selected by switching.
Certain populations may benefit more or less from 1 ADP receptor inhibitor when compared with the other. Secondary analyses have suggested that compared with clopidogrel, prasugrel may have improved benefit-risk ratios in certain high-risk patient populations, such as those who present with STEMI 17 or those with diabetes mellitus. 18 Consistent with this literature, we found that in US practice, the presence of diabetes mellitus was independently associated with switch from clopidogrel to prasugrel, and presentation with STEMI was strongly associated with continuation and discharge on prasugrel. Lesion complexity, such as the presence of intracoronary thrombus, longer length, bifurcation, and multivessel PCI, Figure 2 . Temporal trends in rates of in-hospital ADP receptor inhibitor switch in the overall study population. Frequency of switch from clopidogrel to prasugrel increased from 0% to 7% (P<0.0001). Frequency of switch from prasugrel to clopidogrel increased initially from 6% to 18%, decreased abruptly in the second quarter of 2010 and declined gradually thereafter to 9% at the end of the study period (P<0.0001). Data are presented as percentages or median (25th, 75th percentile). CABG indicates coronary artery bypass grafting; CK-MB, creatine kinase-MB; LAD, left anterior descending artery; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; and TIA, transient ischemic attack. increases the risk of recurrent ischemic events, including stent thrombosis. Data support reduction of stent thrombosis with prasugrel when compared with clopidogrel. 17 Accordingly, the presence of these high-risk angiographic characteristics was associated with switch from clopidogrel to prasugrel. The presence of factors associated with high bleeding risk was the major driver for in-hospital switch from prasugrel to clopidogrel. Because of its higher risk of bleeding, specifically intracranial hemorrhage, the Food and Drug Administration recommends against prasugrel use in patients with previous stroke or TIA, and cautionary use in patients aged ≥75 years or weight <60 kg. There is also increased concern about bleeding with prasugrel when compared with that with clopidogrel among patients undergoing in-hospital CABG 19 and those treated with anticoagulation. 20 The benefit of greater platelet inhibition and reduction of ischemic events by prasugrel is offset by increased bleeding in these populations. It is reassuring that consistent with the available literature and practice guidelines, for the most part, such patients with previous stroke or TIA are switched to and discharged on clopidogrel. However, discharge use of prasugrel in the minority of patients with previous stroke or TIA also observed previously 21 is a concern and requires further educational efforts. In this regard, the use of risk prediction models may allow better selection and tailoring of ADP receptor therapy based on an individual patient's risk profile. 22, 23 Although cost effective compared with on-patent clopidogrel, 24 prasugrel is more expensive when compared with generic clopidogrel and Figure 3 . Temporal trends in rates of in-hospital ADP receptor inhibitor switch among subgroups of patients with ST-segmentelevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome (NSTEACS). Temporal trend in in-hospital switch from clopidogrel to prasugrel was similar for STEMI and NSTEACS. Frequency of switch from prasgurel to clopidogrel was greater among patients with NSTEACS when compared with patients with STEMI at the start of the study period. During the course of the study, consistent with the overall study cohort, similar temporal trends were observed in frequency of switch from prasugrel to clopidogrel in both subgroups. NSTEMI indicates non-STEMI. may be unaffordable by some, especially those without medical insurance or employment. Premature discontinuation of ADP receptor inhibitors is associated with potentially fatal complications, 25, 26 and thus consideration of the ability to cover the cost of prasugrel is a significant determinant of switch from clopidogrel to prasugrel and continuation of prasugrel among those treated initially with it.
Multivessel
Limitations
Despite the many strengths of our study, including the large national sample with detailed clinical, medication, and angiographic information, limitations include the use of observational registry data with lack of available information for the reason to switch ADP receptor inhibitor. In addition, information about the patient or physician preference, allergies, the use of platelet reactivity testing, loading dose at the time of switch, timing of ADP receptor inhibitor switching relative to cardiac catheterization/PCI, and clinical outcomes associated with switching ADP receptor inhibitor were not available. Information on ADP receptor switching after hospital discharge was also not available. Although the proportion of patients with >1 MI event treated with PCI during the study period was relatively small (1.76%), random selection of 1 admission to include in the analysis has potential for bias because previous event may influence choice and decision to switch ADP receptor antagonist. Subjects in this analysis cohort derived after linking 2 registries and using additional exclusion criteria may not be representative of all patients with acute MI. Finally, since the period of study is until June 2011, contemporary switching rates may be underestimated with more wide availability of novel ADP receptor inhibitors.
Conclusions
Clopidogrel and prasugrel are not uncommonly switched inhospital among patients with MI treated with PCI. Switch from initial in-hospital use of clopidogrel to discharge on prasugrel is associated with angiographic and clinical characteristics for increased risk of recurrent thrombotic events, as well as private health insurance coverage to cover the cost of the drug, whereas switch from initial in-hospital use of prasugrel to clopidogrel at discharge is primarily associated with risk of bleeding. Additional studies are required to assess the clinical implications of switching ADP receptor inhibitors on patient outcomes.
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